Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freeport-McMoRan Inc (FCX) vs Revvity Inc (RVTY) Price & Performance

Freeport-McMoRan IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Freeport-McMoRan Inc vs Revvity Inc — how do they compare? Freeport-McMoRan Inc trades at $68.9 (market cap $96.42B), while Revvity Inc trades at $116.04 (market cap $12.91B). The key difference: Freeport-McMoRan Inc is far larger — about 7.5× Revvity Inc's market cap, and Freeport-McMoRan Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals.

FCXRVTY
Market Cap
$96.42B$12.91B
Sector
Basic MaterialsTechnology
52-Week High
$71.73$117.75
52-Week Low
$35.34$82.26
Enterprise Value
$102.70B$15.23B
Dividend Yield
0.87%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freeport-McMoRan Inc

FCX trades at $69.18, down 1.92% today but maintains a bullish technical outlook with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.68 exceeding expectations. Revenue growth remains stable at $25.9B, while profitability metrics show improvement with net income margin expanding to 11.38%. Recent news highlights operational strength at Grasberg mine and positive copper market tailwinds.

FCX presents a compelling investment case with analyst consensus pointing to 6.8% upside to the $73.85 price target. The company's growth initiatives and copper market exposure provide tailwinds, though investors should monitor commodity price volatility and execution risks in expansion projects. With 61% of analysts rating the stock a Buy, institutional sentiment remains positive despite recent price weakness.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Freeport-McMoRan Inc

Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia

Read more on FCX

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY